

Supplemental figure legends.

Supplemental Figure 1. Forest plot for network meta-analysis comparing the relative efficacy of each anti-inflammatory medication on all-cause death. Use of Pexelizumab is associated with lower risk of all- cause mortality in comparison with Veraspladib (OR 0.62, CI 0.37 – 0.99).

Supplemental Figure 2. Forest plot for network meta-analysis comparing the relative efficacies of each anti-inflammatory medication on cardiovascular death.

Supplemental Figure 3. Forest plot for network meta-analysis of myocardial infarction. Use of Canakinumab, Colchicine, Darapladib, and Pexelizumab were associated with lower risk of recurrent myocardial infarction in comparison with Anakinra (OR 0.20, CI 0.04 – 0.79; OR 0.21, CI 0.04 – 0.83; OR 0.22, CI 0.04 – 0.81; and OR 0.22, CI 0.05 – 0.82, respectively).

Supplemental Figure 4. Forest plot for network meta-analysis of revascularization. Use of Colchicine significantly reduced the risk of revascularization in comparison to both Anakinra and Darapladib (OR 0.31, CI 0.11 – 0.84; and OR 0.52, CI 0.29 – 0.93, respectively).

Supplemental Figure 5. Forest plot for network meta-analysis of stroke. Use of Colchicine was associated with significant reduced risk of stroke events after myocardial infarction in comparison to several anti-inflammatory medications including: Darapladib (OR 0.23, CI 0.07-0.57), Pexelizumab (OR 0.23, CI 0.07- 0.64), Losmapimod (OR 0.25, CI 0.07-0.85), Canakinumab (OR 0.30, CI 0.09-0.81), and Veraspladib (OR 0.26, CI 0.07-0.97).

Supplemental Figure 6. Forest plot for network meta-analysis comparing the relative efficacy of each anti-inflammatory medication on major adverse cardiac and cerebrovascular events (MAACE). Colchicine use was associated with significantly lower risk of MACCE when compared to Darapladib (OR 0.69, CI 0.44-0.98), Losmapimod (OR 0.60, CI 0.37-0.93), Anakinra (OR 0.28 CI 0.10 – 0.70) and Varespladib (OR 0.53, CI


0.32-0.83). Both Canakinumab and Pexelizumab were associated with reduced risk of MACCE (OR 0.37, CI 0.13 – 0.95 and OR 0.39, CI 0.14 – 0.96; respectively).

Supplemental Figure 7. network plot of treatments included in this network meta-analysis. Circles represent the intervention as a node in the network, lines represent direct comparisons using randomized clinical trials (RCTs), and the thickness of lines corresponds to the number of (RCTs) included in each comparison.

Supplemental Figure 8. Funnel plots of odds ratios and standard errors to assess the publication bias of all-cause mortality, cardiac mortality, revascularization, stroke, recurrent myocardial infarction, and major adverse cardiac and cerebrovascular events (MACCE).

Supplemental Figure 9. Consistency plot for all-cause mortality, cardiac mortality, revascularization, stroke, recurrent myocardial infarction, and major adverse cardiac and cerebrovascular events (MACCE).

All-cause death




Supplemental Figure 1

All-cause death

Colchicine							
0.95 (0.57 – 1.54)	PEXELIZUMAB						
0.90 (0.49 – 1.53)	0.95 (0.62 – 1.36)	Canakinumab					
0.85 (0.50 – 1.39)	0.91 (0.65 – 1.19)	0.96 (0.64 – 1.43)	Darapladib				
0.83 (0.52 – 1.30)	0.88 (0.70 – 1.07)	0.93 (0.67 – 1.30)	0.98 (0.78 – 1.22)	Placebo			
0.62 (0.00 – 83.33)	0.65 (0.00 – 84.25)	0.70 (0.00 – 91.32)	0.73 (0.00 – 94.61)	0.75 (0.00 – 96.74)	Inclacumab		
0.64 (0.13 – 2.91)	0.66 (0.15 – 2.95)	0.71 (0.15 – 3.24)	0.74 (0.16 – 3.29)	0.76 (0.17 – 3.32)	1.10 (0.01 – 371.60)	ANAKINRA	
0.58 (0.30 – 1.09)	0.62 (0.37 – 0.99)	0.65 (0.37 – 1.13)	0.68 (0.41 – 1.12)	0.70 (0.44 – 1.09)	0.93 (0.01 – 323.10)	0.92 (0.20 – 4.32)	Veraspladib


Cardiovascular death



Supplemental Figure 2

Cardiovascular death

Colchicine							
2.81 (0.09 – 1305.14)	ANAKINRA						
0.64 (0.24 – 1.53)	0.23 (0.00 – 6.68)	Losmapimod					
0.58 (0.23 – 1.23)	0.20 (0.00 – 5.97)	0.90 (0.43 – 1.90)	Canakinumab				
0.47 (0.00 – 154.13)	0.15 (0.00 – 165.26)	0.76 (0.00 – 249.07)	0.84 (0.00 – 271.89)	Inclacumab			
0.57 (0.25 – 1.12)	0.20 (0.00 – 5.80)	0.88 (0.45 – 1.72)	0.99 (0.56 – 1.72)	1.17 (0.00 – 336.00)	Darapladib		
0.54 (0.25 – 1.00)	0.19 (0.00 – 5.40)	0.83 (0.46 – 1.50)	0.93 (0.58 – 1.47)	1.10 (0.00 – 309.80)	0.94 (0.69 – 1.28)	Placebo	
0.46 (0.17 – 1.09)	0.16 (0.00 – 4.96)	0.72 (0.30 – 1.68)	0.80 (0.37 – 1.73)	0.94 (0.00 – 275.60)	0.81 (0.41 – 1.62)	0.86 (0.47 – 1.61)	Veraspladib




Supplemental Figure 3

MI

Canakinumab								
0.96 (0.56 – 1.66)	Colchicine							
0.93 (0.61 – 1.44)	0.98 (0.61 – 1.57)	Darapladib						
0.92 (0.61 – 1.39)	0.96 (0.60 – 1.53)	0.99 (0.71 – 1.34)	PEXELIZUMAB					
0.87 (0.61 – 1.24)	0.91 (0.60 – 1.38)	0.93 (0.73 – 1.17)	0.94 (0.76 – 1.17)	Placebo				
0.69 (0.15 – 2.95)	0.72 (0.16 – 3.10)	0.73 (0.17 – 3.07)	0.74 (0.17 – 3.11)	0.79 (0.18 – 3.25)	Inclacumab			
0.71 (0.40 – 1.24)	0.74 (0.40 – 1.34)	0.75 (0.46 – 1.23)	0.76 (0.47 – 1.25)	0.81 (0.52 – 1.25)	1.03 (0.23 – 4.72)	Losmapimod		
0.58 (0.34 – 1.05)	0.61 (0.34 – 1.14)	0.62 (0.38 – 1.04)	0.63 (0.39 – 1.05)	0.67 (0.44 – 1.06)	0.85 (0.20 – 3.92)	0.82 (0.45 – 1.56)	Veraspladib	
0.20 (0.04 – 0.79)	0.21 (0.04 – 0.83)	0.22 (0.04 – 0.81)	0.22 (0.05 – 0.82)	0.24 (0.05 – 0.86)	0.29 (0.04 – 2.17)	0.29 (0.06 – 1.14)	0.35 (0.07 – 1.39)	ANAKINRA

Revascularization




Supplemental Figure 4

Revascularization

Colchicine							
0.70 (0.37 – 1.32)	Canakinumab						
0.66 (0.24 – 1.82)	0.94 (0.37 – 2.35)	Inclacumab					
0.48 (0.01 – 17.46)	0.69 (0.02 – 24.06)	0.74 (0.02 – 29.36)	Veraspladib				
0.52 (0.29 – 0.93)	0.75 (0.51 – 1.11)	0.80 (0.33 – 1.94)	1.08 (0.03 – 42.29)	Darapladib			
0.49 (0.28 – 0.85)	0.71 (0.51 – 0.98)	0.75 (0.32 – 1.78)	1.02 (0.03 – 39.62)	0.94 (0.76 – 1.17)	Placebo		
0.43 (0.17 – 1.10)	0.61 (0.27 – 1.38)	0.65 (0.21 – 2.05)	0.87 (0.02 – 35.41)	0.82 (0.38 – 1.78)	0.87 (0.41 – 1.83)	Losmapimod	
0.31 (0.11 – 0.84)	0.45 (0.18 – 1.09)	0.48 (0.14 – 1.57)	0.62 (0.02 – 26.14)	0.60 (0.25 – 1.41)	0.64 (0.27 – 1.46)	0.74 (0.23 – 2.26)	ANAKINRA

Stroke



Supplemental Figure 5

Stroke


Colchicine								
0.30 (0.09 – 0.81)	Canakinumab							
0.26 (0.07 – 0.97)	0.90 (0.31 – 2.68)	Veraspladib						
0.25 (0.07 – 0.85)	0.86 (0.34 – 2.16)	0.96 (0.27 – 3.32)	Losmapimod					
0.24 (0.08 – 0.58)	0.81 (0.51 – 1.27)	0.91 (0.33 – 2.35)	0.95 (0.42 – 2.11)	Placebo				
0.23 (0.07 – 0.64)	0.79 (0.40 – 1.56)	0.88 (0.29 – 2.57)	0.92 (0.35 – 2.40)	0.97 (0.59 – 1.61)	PEXELIZUMAB			
0.23 (0.07 – 0.57)	0.76 (0.44 – 1.29)	0.85 (0.31 – 2.30)	0.89 (0.38 – 2.08)	0.94 (0.72 – 1.23)	0.97 (0.55 – 1.71)	Darapladib		
0.11 (0.00 – 1.57)	0.38 (0.01 – 4.56)	0.42 (0.01 – 5.56)	0.44 (0.01 – 5.54)	0.47 (0.02 – 5.49)	0.48 (0.02 – 6.04)	0.50 (0.02 – 5.87)	Inclacumab	
0.00 (0.00 – 0.06)	0.00 (0.00 – 0.20)	0.00 (0.00 – 0.23)	0.00 (0.00 – 0.23)	0.00 (0.00 – 0.24)	0.00 (0.00 – 0.23)	0.00 (0.00 – 0.25)	0.00 (0.00 – 0.67)	ANAKINRA

MACCE

Treatment 1 vs. Treatment 2

O.R. (95% Cr.I.)

- Colchicine versus ANAKINRA
- Canakinumab versus ANAKINRA
- PEXELIZUMAB versus ANAKINRA
- Darapladib versus ANAKINRA
- Placebo versus ANAKINRA
- Inclacumab versus ANAKINRA
- Losmapimod versus ANAKINRA
- Veraspladib versus ANAKINRA
- Colchicine versus Veraspladib
- Colchicine versus Losmapimod
- Colchicine versus Inclacumab
- Colchicine versus Placebo
- Colchicine versus Darapladib
- Canakinumab versus Veraspladib
- Colchicine versus PEXELIZUMAB
- PEXELIZUMAB versus Veraspladib
- Colchicine versus Canakinumab
- Darapladib versus Veraspladib
- Canakinumab versus Losmapimod
- Placebo versus Veraspladib
- Inclacumab versus Veraspladib
- PEXELIZUMAB versus Losmapimod
- Canakinumab versus Inclacumab
- Darapladib versus Losmapimod
- Canakinumab versus Placebo
- Losmapimod versus Veraspladib
- Placebo versus Losmapimod
- PEXELIZUMAB versus Inclacumab
- Canakinumab versus Darapladib
- Inclacumab versus Losmapimod
- PEXELIZUMAB versus Placebo
- PEXELIZUMAB versus Darapladib
- Darapladib versus Inclacumab
- Canakinumab versus PEXELIZUMAB
- Darapladib versus Placebo
- Inclacumab versus Placebo



Heterogeneity (Inform.) = 0.1098


0.01 0.1 1 10
Favours Treatment 1 Favours Treatment 2
Random Effects (Informative Prior)

Supplemental Figure 6


MACCE

Colchicine								
0.76 (0.46 – 1.14)	Canakinumab							
0.72 (0.48 – 1.02)	0.96 (0.67 – 1.37)	PEXELIZUMAB						
0.69 (0.44 – 0.98)	0.91 (0.62 – 1.32)	0.95 (0.72 – 1.24)	Darapladib					
0.65 (0.29 – 1.42)	0.87 (0.39 – 1.89)	0.91 (0.43 – 1.88)	0.96 (0.45 – 2.02)	Inclacumab				
0.67 (0.46 – 0.90)	0.88 (0.64 – 1.20)	0.92 (0.77 – 1.08)	0.97 (0.78 – 1.20)	1.01 (0.49 – 2.09)	Placebo			
0.60 (0.37 – 0.93)	0.80 (0.51 – 1.25)	0.83 (0.58 – 1.20)	0.87 (0.60 – 1.30)	0.92 (0.42 – 2.03)	0.90 (0.66 – 1.25)	Losmapimod		
0.53 (0.32 – 0.83)	0.70 (0.45 – 1.13)	0.74 (0.50 – 1.09)	0.77 (0.52 – 1.17)	0.81 (0.37 – 1.81)	0.80 (0.57 – 1.14)	0.88 (0.56 – 1.43)	Veraspladib	
0.28 (0.10 – 0.70)	0.37 (0.13 – 0.95)	0.39 (0.14 – 0.96)	0.41 (0.15 – 1.02)	0.43 (0.13 – 1.35)	0.42 (0.16 – 1.03)	0.47 (0.16 – 1.21)	0.53 (0.18 – 1.36)	ANAKINRA


Network plot




All cause mortality




Cardiac mortality




Stroke




Revascularization




Myocardial infarction




MACE




Inconsistency analysis




All-cause death




Cardiovascular death



MI



Revascularization



Stroke